Alamoudi Jawaher Abdullah, Li Wenkuan, Gautam Nagsen, Olivera Marco, Meza Jane, Mukherjee Sandeep, Alnouti Yazen
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States.
World J Hepatol. 2021 Apr 27;13(4):433-455. doi: 10.4254/wjh.v13.i4.433.
Hepatobiliary diseases result in the accumulation of toxic bile acids (BA) in the liver, blood, and other tissues which may contribute to an unfavorable prognosis.
To discover and validate diagnostic biomarkers of cholestatic liver diseases based on the urinary BA profile.
We analyzed urine samples by liquid chromatography-tandem mass spectrometry and compared the urinary BA profile between 300 patients with hepatobiliary diseases 103 healthy controls by statistical analysis. The BA profile was characterized using BA indices, which quantifies the composition, metabolism, hydrophilicity, and toxicity of the BA profile. BA indices have much lower inter- and intra-individual variability compared to absolute concentrations of BA. In addition, BA indices demonstrate high area under the receiver operating characteristic curves, and changes of BA indices are associated with the risk of having a liver disease, which demonstrates their use as diagnostic biomarkers for cholestatic liver diseases.
Total and individual BA concentrations were higher in all patients. The percentage of secondary BA (lithocholic acid and deoxycholic acid) was significantly lower, while the percentage of primary BA (chenodeoxycholic acid, cholic acid, and hyocholic acid) was markedly higher in patients compared to controls. In addition, the percentage of taurine-amidation was higher in patients than controls. The increase in the non-12α-OH BA was more profound than 12α-OH BA (cholic acid and deoxycholic acid) causing a decrease in the 12α-OH/ non-12α-OH ratio in patients. This trend was stronger in patients with more advanced liver diseases as reflected by the model for end-stage liver disease score and the presence of hepatic decompensation. The percentage of sulfation was also higher in patients with more severe forms of liver diseases.
BA indices have much lower inter- and intra-individual variability compared to absolute BA concentrations and changes of BA indices are associated with the risk of developing liver diseases.
肝胆疾病会导致肝脏、血液及其他组织中有毒胆汁酸(BA)蓄积,这可能导致预后不良。
基于尿BA谱发现并验证胆汁淤积性肝病的诊断生物标志物。
我们采用液相色谱 - 串联质谱法分析尿样,并通过统计分析比较300例肝胆疾病患者与103例健康对照者的尿BA谱。使用BA指数对BA谱进行表征,BA指数可量化BA谱的组成、代谢、亲水性和毒性。与BA的绝对浓度相比,BA指数的个体间和个体内变异性要低得多。此外,BA指数在受试者工作特征曲线下具有较高的面积,且BA指数的变化与患肝病的风险相关,这表明它们可作为胆汁淤积性肝病的诊断生物标志物。
所有患者的总BA和个体BA浓度均较高。与对照组相比,患者中次级BA(石胆酸和脱氧胆酸)的百分比显著降低,而初级BA(鹅脱氧胆酸、胆酸和猪胆酸)的百分比明显升高。此外,患者中牛磺酸酰胺化的百分比高于对照组。非12α - OH BA的增加比12α - OH BA(胆酸和脱氧胆酸)更为显著,导致患者中12α - OH/非12α - OH比值降低。在终末期肝病评分模型和肝失代偿存在所反映的更晚期肝病患者中,这种趋势更强。在更严重肝病形式的患者中,硫酸化的百分比也更高。
与BA绝对浓度相比,BA指数的个体间和个体内变异性要低得多,且BA指数的变化与患肝病的风险相关。